Boehringer Ingelheim Pharma GmbH and Co. KG [Biberach An Der Riss / Germany]
Boehringer Ingelheim Pharma GmbH and Co. KG [Biberach An Der Riss / Germany] located in BIBERACH AN DER RISS, Germany under the [Boehringer Ingelheim] organization had its last known inspection on 11 Oct 2023. There are 34 known inspections on record.
Site Details
Industries:
Human Drugs,
Biologics
Tags:
Human Drugs,
Packaging,
Label,
Analytical Testing,
Manufacturer,
API Manufacturer,
FDF Manufacturer,
Biologics Manufacturer,
Biologics,
Biologics API Manufacturer
Parent Organization:
Boehringer Ingelheim
Last Inspection Date:
11 Oct 2023
FEI:
3002806518
Redica ID:
Investigators:
Mariza M Jafary,
Omotunde O Osunsanmi,
Dr. Ralph M Bernstein, PhD,
Wayne E Seifert,
Zhong Li, PhD,
Monica Commerford, PhD,
John D White,
Milos Dokmanovic, PhD,
Reyes Candau Chacon, PhD,
Richard Ledwidge (nmi), PhD,
Zhihao Qiu (Peter), PhD,
Donald C Obenhuber, PhD,
Erika V Butler,
Julie D Bringger,
Virgilio F Pacio, CSO,
Mary E Storch,
Bo Chi, PhD,
Walter N Lange,
Mark Brunswick, PhD,
Brenda W Uratani, PhD,
Robert W Jennings,
Qing Joanna Zhou, PhD,
Kalavati Suvarna, PhD,
Anh M Lac,
Mihaly S Ligmond,
Eliezar Ramos,
Yanming An, PhD,
Richard W Berning,
Kurt A Brorson, PhD,
Rose M Ashley,
Diane L Raccasi,
Felix Maldonado,
Christopher Downey, PhD,
Zerita White,
Ann L Demarco,
Kevin A Gonzalez,
Prabhu P Raju,
Veronica Fuentes, MS,
Anita Narula, PhD,
Thuy T Nguyen, LCDR,
Azza Talaat,
Doan T Nguyen, PharmD,
Michael Shanks, MS,
Mra Munizn,
Kathleen R Jones, PhD,
Michelle Y Clark Stuart,
Ziyang Su, PhD
Boehringer Ingelheim Pharma GmbH and Co. KG [Biberach An Der Riss / Germany]'s Most Recent Documents
Publish Date | Document Type | Title |
---|---|---|
September, 2019 | FDA 483 | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483, 2019-09-19 |
September, 2018 | FDA 483 | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483, 2018-09-21 |
July, 2018 | FDA 483 | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483, 2018-07-10 |
November, 2015 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2015-11-13 |
November, 2015 | FDA 483 | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483, 2015-11-13 |
Experience Redica Systems’s NEW site dashboards and profiles
Redica Systems customers can leverage the full Quality and Regulatory Intelligence suite, with powerful analysis covering thousands of sites around the world. You can search by FEI, or more powerfully, by the Redica ID, our universal identifier for global life sciences manufacturing sites, an industry first.
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Loading...
Site Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to our extensive inventory of site profiles, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more